Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan

Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan

Although vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) induce effective immune responses, vaccination with booster doses is necessary because of waning immunity. We conducted an open-label, non-randomized, single-arm study in adults in Japan to ass...

Full description

Bibliographic Details
Main Authors: Junko Terada-Hirashima, Yuki Takamatsu, Yosuke Shimizu, Yukari Uemura, Junko S. Takeuchi, Noriko Tomita, Kouki Matsuda, Kenji Maeda, Shohei Yamamoto, Ami Fukunaga, Norio Ohmagari, Ayako Mikami, Kengo Sonoda, Mugen Ujiie, Hiroaki Mitsuya, Wataru Sugiura
Format: Article
Language:English
Published: Taylor & Francis Group 2023-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
covid-19
sars-cov-2
covid-19 vaccine
inactivated vaccine
side effects
adverse events
vaccine safety
neutralizing antibody
kd-414
Online Access:http://dx.doi.org/10.1080/21645515.2023.2193074

Internet

http://dx.doi.org/10.1080/21645515.2023.2193074

Similar Items